Medtronic's $700M Cornerstone Robotics Deal Expands Surgical Portfolio

M&A · Partnership
โดย Simply Wall St·US·Read original
Summary · why it matters

Medtronic plc has announced a partnership with Cornerstone Robotics, committing about US$700 million to secure distribution rights for Cornerstone's Sentire surgical system in select markets outside the U.S., where it will complement Medtronic's Hugo robotic-assisted surgery platform. This move broadens Medtronic's robotic surgery offerings, providing hospitals and surgeons with more choices across complementary platforms that integrate into the company's connected surgical ecosystem, potentially boosting adoption of minimally invasive procedures. The partnership adds to Medtronic's investment narrative, which already includes a US$0.72 quarterly dividend and 49 consecutive years of increases, highlighting a balance between innovation spending and shareholder returns. However, the deal does not fundamentally alter the main risk that large new platforms may scale slower or cost more than expected. Medtronic's narrative projects US$41.5 billion revenue and US$6.6 billion earnings by 2029, requiring 4.5% yearly revenue growth and a roughly US$1.8 billion earnings increase from US$4.8 billion today, with a fair value estimate of US$98.00, an 8% upside to its current price.

Impact on stocks 1

Robotics & Physical AI▲ · 1 stocks
Medtronic PLC
MDT
▲ PositiveDemandrelevance

Medtronic commits ~$700M for distribution rights to Cornerstone's Sentire surgical system, broadening its robotic surgery offerings and potentially boosting adoption of minimally invasive procedures.

Theme Impact 1

Off-coverage companies 1

Cornerstone RoboticsPrivate▲ Positive
Demandrelevance

Cornerstone Robotics gains a ~$700M partnership giving its Sentire surgical system distribution through Medtronic in select markets outside the U.S.

Related news

▲

Medtronic Wins FDA Clearance for LigaSure on Hugo Robotic Surgery System

Medtronic received FDA clearance for its LigaSure vessel-sealing device on the Hugo robotic surgery system in the United States. The authorization allows LigaSure to be used on the Hugo platform for soft-tissue procedures in U.S. hospitals and surgical centers, integrating a widely used vessel-sealing tool with Medtronic's robotic-assisted surgery platform for general surgery use. The clearance ties a familiar energy device into a newer robotic platform, helping Hugo look less like an isolated project and more like part of a multi-platform ecosystem as Medtronic competes with peers such as Intuitive Surgical and Johnson & Johnson. Medtronic's US$118.7 billion scale in medical equipment gives it a broad installed base where new tools on the Hugo robotic system can plug into existing surgical workflows. The unresolved piece is scale, as analysts have already flagged execution risks in major product ramp-ups and the approval does not yet answer how quickly hospitals will adopt Hugo for a wider mix of soft-tissue procedures.
MDT ▲
Robotics & Physical AI ▲
Simply Wall St·3hRead more →
▲2

Intuitive Surgical Wins CE Mark for da Vinci SP in Transvaginal Gynecologic Procedures

Intuitive Surgical announced that its da Vinci SP surgical system received CE mark approval in Europe for transvaginal gynecologic procedures, the platform's first such indication globally. The authorization expands the SP system's approved applications in women's health and extends its natural orifice surgery portfolio beyond transoral and transanal procedures, supporting the company's strategy of growing the platform through new indications rather than relying solely on new system placements. The approval could help increase utilization of the existing da Vinci SP installed base across Europe, a key driver of recurring revenue through instruments, accessories and service revenue. During its second-quarter 2026 earnings call, management highlighted that SP procedures surged 61% year over year, driven by expanded indications, new instrumentation and broader adoption, while the company placed 38 SP systems in the quarter, up from 23 a year ago, taking the global installed base to 445 systems. Intuitive Surgical also noted that more than 1,000 peer-reviewed publications support the safety and efficacy of the da Vinci SP platform.
ISRG ▲
Robotics & Physical AI ▲
Zacks Investment Research·2dRead more →

Johnson & Johnson Targets Double-Digit Growth by End of Decade

Johnson & Johnson said it remains on track to grow through biosimilar competition for STELARA and expects its medicines, medical devices and pipeline to support accelerating growth through the end of the decade. Speaking at a Morgan Stanley event, Chief Executive Officer and Chairman Joaquin Duato said the company's current guidance calls for 6.5% adjusted operational sales growth and 7.3% adjusted earnings-per-share growth in 2026, with total revenue expected to exceed $100 billion for the first time. Duato said 2027 should be a better year than 2026 and that the company has line of sight to double-digit growth by the end of the decade, with more detail to come at an enterprise business review in early December. John Reed, executive vice president of Innovative Medicine and R&D, said Johnson & Johnson has 12 molecules that have achieved proof of concept and are in Phase III development, and that beyond DARZALEX it has 10 marketed medicines still early in their product life cycles. Capital allocation priorities center on launches such as ICOTYDE, INLEXZO, RYBREVANT, IMAAVY and the OTTAVA robotic surgical system, plus pipeline funding and earlier-stage business development, including the recent acquisitions of Halda Therapeutics and Firefly Bio and a collaboration with an option to acquire Sail. Duato said the company can reach double-digit growth this decade without acquisitions but views M&A as a way to reinforce growth into the following decade.
JNJ ▲
Biotech & Genomic Medicine ▲Robotics & Physical AI
MarketBeat·4dRead more →
© 2026 MarketDXNews